Vanda Pharmaceuticals (VNDA) Cash from Operations Growth (5y) (2015 - 2026)
Vanda Pharmaceuticals (VNDA) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Vanda Pharmaceuticals | 310.98 Mn | 108.67 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.48% |
| Dec 31, 2025 | -28.65% |
| Sep 30, 2025 | -39.98% |
| Jun 30, 2025 | -21.39% |
| Mar 31, 2025 | -105.38% |
| Dec 31, 2024 | -16.93% |
| Sep 30, 2024 | -34.68% |
| Jun 30, 2024 | -18.51% |
| Mar 31, 2024 | -4.73% |
| Dec 31, 2023 | -17.55% |
| Sep 30, 2023 | -17.46% |
| Jun 30, 2023 | -38.03% |
| Mar 31, 2023 | 80.98% |
| Dec 31, 2022 | 22.13% |
| Sep 30, 2022 | 42.72% |
| Jun 30, 2022 | 35.19% |
| Mar 31, 2022 | 22.47% |
| Dec 31, 2021 | 89.58% |
| Sep 30, 2021 | 49.91% |
| Jun 30, 2021 | 50.92% |